



**PATHWAYS4KIDS**

Supporting Evidenced Based Practices

# Choosing the Right Path: Growing a Clinical Pathways Program

*Jane Lavelle, MD  
Rebecca Kasper, MSN  
Brandon Ku, MD*

*February 10, 2026*



 **Children's Hospital  
of Philadelphia**  
Center for Healthcare  
Quality & Analytics





**Volume of medical knowledge exceeds an individual clinician's capacity to retain it..**

## The Rapid Evolution of Medical Knowledge

Medical knowledge estimated to double every 50 years

1950

Medical knowledge doubling every 7 years

1980

Doubling time reduced to every 3.5 years

2010

Estimated Doubling time - 73 days

2025





# Knowing – Doing Gap



## Unwarranted variation in Medical Care

Adults receive 54.9% of recommended care  
Children receive 40% of recommended care

## Overuse of testing, overtreatment

- Culture of perfection
- Clinical uncertainty
- Lack of evidence
- Malpractice risk
- Patient request
- Payment structure

## Underuse of testing, treatment

- Knowledge, process gap
- Access to healthcare
- Social determinants







# Organizational Complexity, Interdisciplinary Teamwork





# A Path Toward a Best Practice & Team Mental Model



- Learn More**
- [Hemophilia Overview](#)
  - [RN Learning Module](#)
  - [RN Knowledge Assessment](#)
  - [MD/CRNP Learning Module](#)
- Journals & Articles**
- [Hemophilia A - N Engl J Med, 1994 Jan](#)
  - [Haemophilias A and B - Lancet, 2003 May](#)
- Related Links**
- [National Hemophilia Foundation \(NHF\)](#)

Evidence, expert consensus, Whiteboard, Word document  
Posted CHOP Internet, 2005, Paper Order Set





# Bottom-up and Top-Down



## Emergency Department






# Key Elements of Quality Improvement

## Interdisciplinary Team



## Process



## Education, Clinical Decision Support, Measurement

ED Pulmonary Embolism Pathway

- 1 CBC, Packed With Differential STAT ONE TIME - NOW/SCHEDULED
- 2 Basic Metabolic Panel STAT ONE TIME - NOW/SCHEDULED
- 3 Hepatic Function Panel STAT ONE TIME - NOW/SCHEDULED
- 4 D-Dimer STAT ONE TIME - NOW/SCHEDULED
- 5 Prothrombin (PT) STAT ONE TIME - NOW/SCHEDULED
- 6 Hainometric Pepside STAT ONE TIME - NOW/SCHEDULED
- 7 PT/INR STAT ONE TIME - NOW/SCHEDULED
- 8 PTT Profile STAT ONE TIME - NOW/SCHEDULED
- 9 Fibrinogen-COMBO STAT ONE TIME - NOW/SCHEDULED

ESi Practice Advisory - Aug, Marc


This patient meets criteria for a sepsis huddle due to tachycardia and a risk factor (high-risk condition, altered mental status, or delayed cap refill).

Please take the following actions based on triage ESI level:

ESI 1: Move to Resuscitation Bay  
ESI 2: Available Room (Team 1-3) - Move to room and notify team attending for huddle.  
No Available Room - Call Team 1 Attending to triage for sepsis huddle.

\*\*\* Document the sepsis huddle outcome by clicking the hyperlink below or via the nursing narrator.

Open Order Set: ED Sepsis Pathway preview  
Click Here to Document the Outcome of the Sepsis Huddle






# Hypothesis

- Decrease Evidence to Care Gap
- Common Mental Model
  - Enhance Teamwork
  - Expectations around communication
  - Improved care process
- Care Model Enhancement
  - Clinicians function at top of license
  - Role specific jobs
- Implementation Strategies
  - Education
  - Chief complaint-based Order Set
  - RN Initiated Orders
  - Practice alerts
- Meaningful measurement
- Continuous Learning



# SCD Fever: Defining Low Risk Criteria, 2010



If all **Low Risk Criteria** met, patients are eligible for ceftriaxone and discharge after Hematology consultation

**CLINICAL**

- >12 mos
- Well-appearing
- Good VS
- Tolerating po well
- No concern for complications
- Sequestration
- Acute chest syndrome
- VOC requiring IV analgesia
- No new hypoxia
- O<sub>2</sub> sat ≥ 92% if baseline not known **or**
- RA sat < 3% below baseline

**LABS/X-RAY FINDINGS**

- Hgb > 5
- Reticulocyte count >1% (unless Hgb >10)
- No significant drop Hgb (>2g)
- WBC >5K and < 30K
- Chest x-ray (if indicated) without infiltrate
- UA (if indicated)

**SCD PMH/SOCIAL**

**No history of:**

- Ceftriaxone in preceding 8 weeks
- Bacteremia
- Sepsis
- Sequestration
- Recent antibiotic treatment
- Multiple visits for same febrile illness

**No history of:**

- Non-compliance with penicillin prophylaxis
- Missing, delayed immunizations

Low likelihood of follow-up:

- No phone
- No transportation
- Currently in shelter
- Missed appointments

## ED Sickle Cell Discharge

### Diagnosis

#### Sickle Cell Diagnosis

- Sickle-Cell Disease with Vaso-Occlusive Pain [282.69D]
- Sickle-Cell Disease, Unspecified [282.60]
- Dactylitis [686.9AC]
- Priapism [607.3]
- Headache [784.0]
- Migraine [346.90A]
- Back Pain [724.5E]
- Other Chest Pain [786.59]
- Abdominal Pain [789.00AF]
- Leg Pain [729.5H]
- Viral Syndrome [079.99B]
- Fever [780.60C]
- Nausea with vomiting [787.01]

### Medications

#### Sickle Cell Pain Medications

### ED Nurse Practitioner Follow-Up

#### ED NP Follow-Up

- Message to ED NP Follow-up (lab test/medical issue)

### ED Sickle Cell Hematology Fever Follow-Up

#### ED Sickle Cell Hematology Fever Follow-Up

- Message to Hematology for ED Sickle Cell Fever Follow-Up  
Internal referral

### Disposition and Follow-Up

#### Dispo and Follow-Up Information

- Discharge [edit](#)
- Follow-up with PCP tomorrow
- Follow-up with PCP within 3-5 days
- Follow-up with PCP as needed
- Follow-up with your regular provider
- Follow-up with CHOP Hematology at 215-590

### Discharge Instructions

#### Sickle Cell Discharge Instructions

- Work School Excuse - click edit to complete
- Sickle Cell Pain

#### Non-English Discharge Instructions






# SCD Fever Outpatient Care

## Our Decision is NO Admission!

### Proportion of Patients Discharged from the Emergency Department






These blips are pts >18 who present to CHOP and were transferred to the adult hospital next door

These are patients since the new Pathway and process went live

Go Live



## No bad outcomes

### Low Risk SCD Patients with Fever Discharged from ED






# Changing Culture



VS





# Chairs Initiative, 2009-2011




## Collaborative Clinical Pathways

### GOAL:

To develop the infrastructure required to support the ongoing development, implementation, and evaluation of expert consensus and evidence-based practices for clinical conditions in patients whose care crosses multiple clinical settings and is provided by multiple clinical groups.

**Blood Culture Positive Inpatient Treatment of Febrile Young Infants (0-56 Days Old)**



## Neonatal Fever Pathway

- Created a standard of care for the treatment of infants < 56 days of age with fever in both Emergency Department and Inpatient settings
- Educated bedside clinicians
- Developed Quality Metrics

### Quality

- Appropriate use of antibiotics
- Reduced use of acyclovir
- Appropriate use of laboratory testing
- Standardized interpretation of negative cultures
- Early discharge if viral studies positive

### Efficiency

- Decreased ED, hospital length of stay

### Education

- RN, MD, all team members

### The Children's Hospital of Philadelphia

#### Febrile Neonates Scorecard - DRAFT

Data as of November 2009

	Current Month Indicator Status	Best Practice	Target	Current Month Median	Current Year Trend
<b>ED Arrival to Antibiotics in Min</b>		232.5	325.0		
ED Arrival to Antibiotics <= 28 days		130.0	200.0	244.0	
ED Arrival to Antibiotics > 28 days		180.0	240.0	341.0	
<b>ED Arrival to Urine Cult in Min</b>		90.0	108.2	148.0	
<b>ED Arrival to LP in Min</b>		120.0	179.8	258.5	
<b>ED Arrival to Phys Eval in Min</b>		28.5	47.0		
<b>Phys Eval to Dec to Admit in Min</b>		99.8	153.5		
Phys Eval to Dec to Admit <= 28 days		75.0	159.0		
Phys Eval to Dec to Admit > 28 days		123.8	153.0		
<b>Dec to Admit to MI Report in Min</b>		78.0	69.5		
<b>MI Report to PT to Floor in Min</b>		33.8	50.5		
		<b>Prior Year Median</b>	<b>Current Month Median</b>		
<b>Hospital Length of Stay in Hrs</b>	N/A Since No Target	55.0	55.0		
Hospital Length of Stay <= 28 days		59.0	54.0		
Hospital Length of Stay > 28 days		53.0	56.0		
<b>Hospital Charges/Cost</b>	N/A Since No Target	\$12,425.34	\$16,296.68		
Hospital Charges/Cost <= 28 days		\$13,067.18	\$14,787.40		
Hospital Charges/Cost > 28 days		\$11,782.83	\$16,610.68		
<b>Ev Per Sent When Appropriate</b>	N/A Since Target is 100%	100.0%	0.00%		

FY11 Care Model Operating Plan  
FY12 Operating Plan





# Highlights of Pathway Impact

ED Sickle Cell with  
Fever Pathway

- Admission rate decreased by 33%

ED Oncology  
Patient with Fever  
Pathway

- Admissions decreased by 16% in ED, 33% in Oncology clinic

ED Anaphylaxis  
Pathway

- Admission rate decreased by 60%

ED Ventricular  
Shunt Pathway

- CT radiation exposure decreased by 50%, decreased shunt surveys from 62% to 5%

AIS Spinal Fusion  
Rapid Recovery  
Pathway


- Post-op LOS reduced by median of 2 days





Become a **Continuously Learning Healthcare System**, the Clinical Pathways Program will enable CHOP to:

- Engage **multidisciplinary** teams in embedding evidence & local expertise into the delivery of pediatric medical care
- Reduce **unnecessary variation** in care
- Reliably **measure** the quality of care we provide
- **Iteratively incorporate new evidence** and information from measurement and clinician/family feedback into care recommendations.





# Clinical Pathways Program - 2017

  
Clinical  
Pathways  
Program  
  
2017





# Clinical Pathways Program - 2022

  
Clinical Pathways Program  
2022





# Clinical Pathways Team



**Medical Director**  
[Jane Lavelle, MD](#)



**Program  
Manager**  
[Becca Kasper, RN](#)



**Associate Medical  
Director**  
[Brandon Ku, MD](#)



**Improvement  
Advisor**  
[Pamela Wentz, RN](#)



**Improvement  
Advisor**  
Kathy Houg, CRNP



**Improvement  
Advisor**  
[Nina Capoferri, RN,  
BSN](#)



**Senior Interactive  
Designer**  
Stephen Crawford,  
BS





# Pathway Development

## Clinical Pathways Request for Proposal

AAA  
 

Clinical Pathways are intended to standardize care for a specific clinical chief complaint, disease, process/procedure, or episode of healthcare in a specific population by bringing guidelines/ evidence/ expert consensus to the bedside through detailed steps, timeframes and criteria-based progression in care when appropriate. Pathways assist in standardizing care for 80% of the pathway population, for the remaining 20%, individual clinical decision making by the team is required. Variation resulting from specific patient characteristics is preserved; variation from the individual provider is eliminated.

Clinical Pathways will be posted on the webpage (<https://www.chop.edu/pathways>) for internal and external (public) use. The information below will assist the CHQA team in determining if a clinical pathway is the appropriate tool to solve the problem you've identified and if so, where your pathway will be placed in the development queue. Of note, after RFP submission, most teams will not begin pathway development for at a minimum several months.

<b>Request Type:</b> <i>* must provide value</i>	<input type="radio"/> New Pathway <input type="radio"/> Significant Update to Existing Pathway	<a href="#">reset</a>
<b>Submitter Name:</b> <i>* must provide value</i>	<input type="text"/>	
<b>Pathway Name:</b> <i>* must provide value</i>	<input type="text"/>	
<b>Team Leads Names, Roles, Units/Divisions:</b> <i>* must provide value</i>	<input type="text"/> <small>Required Team Leads at least 2 multidisciplinary clinical experts for given clinical problem or process - Physician-nurse dyad suggested; other content experts may be added/substituted based on content.</small>	
<b>Team Members Names, Roles, Units/Divisions:</b> <i>* must provide value</i>	<input type="text"/> <small>Team Members represent ALL important stakeholders for this clinical problem or process - (i.e. nursing, social work, nutrition, etc. Please include APP when possible).</small>	





# Prioritization Matrix

<b>Initial Screen</b>	<b>Pathway Alternatives</b>	CDS, Policy/Procedure
<b>Impact</b>	<b>Supporting Evidence</b>	Guidelines, Research, Expert Consensus
	<b>Quality Impact Themes</b>	Improve Outcomes, Increase Effectiveness/Efficiency, Promote Health & Healthy Communities, Reduce Disparities, Reduce Suffering, Reduce Time Needed to Care, Reduce Unnecessary Care, Keeping Kids out of the Hospital
	<b>Safety</b>	Harm Prevention, Employee Safety, RCA/ACA, Public Health Urgency, Delayed Diagnosis
	<b>Organizational Benefit</b>	Employee Engagement, Alignment with Strategic Plan, Employee Well Being, Financial Stewardship
	<b>Size/Scope of the Problem</b>	Appropriately Defined Scope, Care Areas Impacted, Patient Volume, High Risk/Low Volume
<b>Effort</b>	<b>SMARTIE Aim</b>	Clinical Outcomes
	<b>Team's Commitment</b>	Previous Pathway Work, Support From Division Leadership





# CHOP Improvement Framework

## DEFINE



Clinical problem  
identified by local  
teams

## DIAGNOSE



RFP submission  
Supporting evidence,  
quality impact themes,  
safety, SMARTIE Aim,  
size/scope, team  
commitment

## TEST & IMPLEMENT



Pathways team helps  
map the process and  
identify appropriate  
interventions based  
on evidence and  
expert consensus  
  
Published pathway  
enhanced with CDS

## SUSTAIN & SPREAD



Ongoing data  
measurement and  
pathway updates  
every 3 years





- Evidence, expert consensus
- Local data
- Clinical Decision Support
  - Use of Phrase Health to aid in review, analysis

## New Pathways

[Botulism, Infant, ED, Inpatient and PICU](#)

[Thyroid Function in Newborns, N/ICU](#)

[Acute Bacterial Rhinosinusitis, Primary Care,  
Emergency Department, Inpatient](#)

[Urticaria or Angioedema, ED, Primary Care](#)

[Lipid Screening, Primary Care](#)

## Revised Pathways

[Periacetabular Osteotomy \(PAO\), Inpatient](#)

[Hyperbilirubinemia/Jaundice, All Settings](#)

[Pulmonary Embolism, Acute, ED, ICU and  
Inpatient](#)

[Mpox, ED, Outpatient Specialty Care and  
Primary Care](#)

[Sexually Transmitted Infections \(STI\) in  
Adolescents, ED, Primary Care](#)





- Has the process or care become standard?
- Are there better tools now available to meet the team's needs?
- Web analytics





Care Area	Number of Pathways
Emergency Department, Urgent Care	90
Inpatient Care	87
Intensive Care (PICU, CICU, N/IICU)	76
Outpatient Specialty Care	41
Primary Care	46
Behavioral Health	17





# Clinical Pathways Team



**Medical Director**  
[Jane Lavelle, MD](#)



**Program  
Manager**  
[Becca Kasper, RN](#)



**Associate Medical  
Director**  
[Brandon Ku, MD](#)



**Improvement  
Advisor**  
[Pamela Wentz, RN](#)



**Improvement  
Advisor**  
Kathy Houg, CRNP



**Improvement  
Advisor**  
[Nina Capoferri, RN,](#)  
[BSN](#)



**Senior Interactive  
Designer**  
Stephen Crawford,  
BS





# Pathway Template

## Emergency Department and Inpatient Clinical Pathway for Evaluation/Treatment of Febrile Infants ≤ 56 Days Old with Community Onset Fever

Goals and Metrics  
Provider Resources

**Related Pathway**  
Urinary Tract Infection (UTI), All Settings  
Bronchiolitis, Inpatient  
Sepsis, ED, Inpatient, PICU  
Sepsis, N/ICU

**Summary of Pathway Updates**  
Adapted from AAP Guidelines 2021

Febrile Young Infant ≤ 56 Days Old with Community Onset Fever

Triage (Critical/Acute)  
ED nursing pathway standing order set: Febrile Young Infant

**Ill-appearing or as clinically indicated:**  
Sepsis Huddle  
Sepsis Pathway  
Sepsis N/ICU  
Sepsis ED, Inpatient, PICU

**ED Team Assessment and Bedside Procedure**  
History and Physical  
IV and Laboratory Studies  
POC glucose as needed  
Consider HSV and Other Diagnostic Testing  
If 0-21 days old: LMX to LP site, LP tray at bedside

**Inclusion Criteria**  
0 to 56 days of age  
Recorded temp ≥ 38.0° C (100.4° F) in past 24 hrs  
Well-appearing

**The following infants may have higher risk of invasive bacterial infection. IMs alone should not be used for risk stratification:**  
Premature birth < 37 wks gestation  
Prolonged N/ICU stay  
Complex Medical History  
Physical Exam with Concern for Focal Bacterial Infection

Lab Study	Definition of Abnormal
Procalcitonin	> 0.5 ng/mL
Absolute Neutrophil Count	> 4000 neutrophils/μL < 1000 neutrophils/μL
Urinalysis with Reflex to Microscopy	Any leukocyte esterase (LE) on dipstick or > 5 WBCs per hpf
CSF	0-28 days: ≥ 15 WBC/μL 29-56 days: ≥ 9 WBC/μL

**Antimicrobials: Recommendations, Dosing, and Rationale**

**Evidence**  
[Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old](#) ☞  
[Use of Procalcitonin Assays to Predict Serious Bacterial Infection in Young Febrile Infants](#) ☞  
[Time to Pathogen Detection for Non-Ill Versus Ill-Appearing Infants ≤60 Days Old With Bacteremia and Meningitis](#) ☞  
[Prevalence of Bacterial Meningitis Among Febrile Infants Aged 29-60 Days With Positive Urinalysis](#) ☞  
[Systematic Review and Meta-analysis](#) ☞  
[Validation of the "Step-by-Step" Approach in the Management of Young Febrile Infants](#) ☞  
[View All Evidence](#)

**Educational Media**  
[Approach to the Febrile Young Infant \(FYI\)](#) ☞  
[Episode 8: The Febrile Infant - Join host Dr. Bob Belfer as he talks to PEM Experts Dr. Rich Scarfone and Dr. Prashant Majahan About how to Approach the Infant with a Fever](#) ☞

**Posted:** August 2010  
**Revised:** August 2023  
**Authors:** B. Scarfone, MD; P. Gala, MD; L. Sartori, MD; B. Ku, MD; J. Lavelle, MD; MK. Abbadessa, ACCNS-P; L. Bell, MD; E. Kane, MD; E. Kahle, MD; C. Jacobstein, MD; K. Chiotos, MD; T. Matjian, PharmD  
**Editors:** Clinical Pathways Team

Infants 0-21 Days Old

Infants 22-28 Days Old

Infants 29-56 Days Old

Blood culture  
UA, urine culture  
HSV Testing  
Perform LP

CBC, blood culture  
Inflammatory Markers (IMs); Procalcitonin, ANC  
UA, urine culture  
Consider HSV Testing

CBC, blood culture  
Inflammatory Markers (IMs); Procalcitonin, ANC  
UA, urine culture  
Consider HSV Testing

Infants with Bronchiolitis

Abnormal UA or ≥ 1 abnormal IM  
Perform LP

Normal UA  
Normal IMs  
No LP

Normal UA  
≥ 1 abnormal IM  
Perform LP

Abnormal UA  
Normal IMs  
No LP

Abnormal UA  
Abnormal IMs  
LP Guidance

Normal UA  
Normal IMs  
No LP

Antimicrobials  
Acyclovir

Antimicrobials

No antimicrobials

Antimicrobials

Antimicrobials

Antimicrobials

Discharge home w/follow-up or  
Admit w/o antimicrobials as indicated for etiologies other than serious bacterial infections

**Admit from Emergency Department**

LP Indicated, but No CSF Obtained

Any Positive Culture or HSV PCR

Discharge Criteria





## Filter By

### Settings

[Clear all](#)

- Emergency (92)
- Inpatient (89)
- ICU (84)
- Primary care (46)
- Outpatient specialty care (41)
- Urgent care (36)

### Body System

[Clear all](#)

- Allergy and Immunology
- Behavioral Health
- Cardiac
- Endocrine
- Gastrointestinal/Nutrition
- General
- Genitourinary
- HEENT
- Hematology/Oncology
- Infectious Diseases
- Musculoskeletal
- Neurologic
- Respiratory
- Skin
- Trauma

[22q11.2 Hypocalcemia Screening/Treatment, Inpatient, Outpatient Specialty Care and PICU](#)[Abdominal Solid Organ Injury, ED, Inpatient, and ICU](#)[Abuse Physical, ED](#)[Abuse, Physical, Outpatient Specialty and Primary Care](#)[Abuse, Sexual, ED](#)[Acute Bacterial Rhinosinusitis, Primary Care, Emergency Department, Inpatient](#)[ADHD, Primary Care](#)[Airway Clearance/Hyperinflation Therapy, ICU and Inpatient](#) - Updated[Airway, Difficult/Critical, All Settings](#)[Anaphylaxis, ED](#)[Anaphylaxis, Inpatient](#)[Anaphylaxis, Outpatient Specialty and Primary Care](#)[Anesthesia/Sedation, Preoperative Care and Preparation, ED and Inpatient](#)[Ankyloglossia \(Tongue-Tie\), Outpatient Specialty Care, Primary Care](#)[Anti-NMDA Encephalitis, Inpatient](#)[Anxiety Disorder and OCD, Outpatient Behavioral Health and Primary Care](#)[Aplastic Anemia, All Settings](#) - Updated[Appendicitis, Inpatient](#)[Lymphatic Disorders, Neonatal, Inpatient](#)[Malnutrition \(Undernutrition\), Inpatient](#)[Malnutrition Weight Loss and Eating Disorders, ICU and Inpatient](#)[Malnutrition, Infant, Outpatient Specialty Care, Primary Care](#)[Malnutrition/Failure to Thrive, Infant, Inpatient](#)[Measles Suspected Exposure or Infection, ED, Outpatient Specialty and Primary Care](#)[Meningitis, Suspected, ED, Inpatient, ICU](#)[Micrognathia-Retrognathia, Neonate/Infant, N/ICU](#)[Migraine Headache, ED](#)[Migraine Headache, Inpatient](#)[Mitochondrial Disease, ED and Inpatient](#)[Mpx, ED, Outpatient Specialty Care and Primary Care](#) - Updated[Multiple Patient Events and Mass Casualty Incidents, ED](#)[Multisystem Inflammatory Syndrome \(MIS-C\)](#)[Myelomeningocele/Myeloschisis, Neonatal, N/ICU](#)[NAS/NOWS, Neonatal, Inpatient](#) - Updated[Neck Space Infection, Deep, ED, Inpatient](#)[Neonatal Seizure/Status Epilepticus Clinical Pathway, N/ICU](#)[Nephrolithiasis, ED](#) - Updated

## Clinical Pathways Library

Find a Clinical Pathway





# Getting the Word Out





# Clinical Pathways Program - 2022

  
Clinical  
Pathways  
Program  
  
2022








# ED, Inpatient: Diabetic Ketoacidosis Pathway

Emergency Department, ICU and Inpatient Clinical Pathway for Evaluation/Treatment of Children with Suspected Diabetic Ketoacidosis (DKA)

- Goals and Metrics
- Patient Education
- Provider Resources

**Related Pathways**  
Type 1 DM and Acute Illness, ED  
Diabetic Ketoacidosis without Acidosis, Inpatient



Cerebral Edema Risk Treatment

**Care Goals**  
Frequent MS, VS, PE assessment  
Initial NS bolus over 1st hr  
Insulin to start after 1st NS bolus  
Decrease blood glucose (BG)  
50-100 mg/dL/hr  
Adjust dextrose  
Based on hourly BG  
Adjust K+  
Based on q2hr BMP/mag/phos  
ECG for < 2.5 or K+ > 6


<b>IVF Rehydration, Electrolytes, Glucose</b>	Additional NS or LR bolus as indicated by PE, VS Start NS 1.5x maintenance until electrolyte results Then start 2 bag (D10NS, NS) system: Dextrose provided based on BG Electrolyte content based on K+ level Rate 1.5x maintenance																										
	<table border="1"> <thead> <tr> <th rowspan="2">Blood Glucose</th> <th rowspan="2">Dextrose</th> <th colspan="3">Concentration of Potassium in IVF: KCL + KPhos</th> </tr> <tr> <th>Serum K</th> <th>KCL</th> <th>KPhos</th> </tr> </thead> <tbody> <tr> <td>&lt; 200</td> <td>All D10</td> <td>&lt; 4</td> <td>30 mEq</td> <td>30 mEq, 20.4 mM</td> </tr> <tr> <td>200-299</td> <td>Half D10, half NS</td> <td>4.5-4</td> <td>20 mEq</td> <td>20 mEq, 13.6 mM</td> </tr> <tr> <td rowspan="2">&gt; 300</td> <td rowspan="2">All NS</td> <td>5.5-6</td> <td>10 mEq</td> <td>10 mEq, 6.8 mM</td> </tr> <tr> <td>&gt; 6</td> <td>None</td> <td>None</td> </tr> </tbody> </table>	Blood Glucose	Dextrose	Concentration of Potassium in IVF: KCL + KPhos			Serum K	KCL	KPhos	< 200	All D10	< 4	30 mEq	30 mEq, 20.4 mM	200-299	Half D10, half NS	4.5-4	20 mEq	20 mEq, 13.6 mM	> 300	All NS	5.5-6	10 mEq	10 mEq, 6.8 mM	> 6	None	None
Blood Glucose	Dextrose			Concentration of Potassium in IVF: KCL + KPhos																							
		Serum K	KCL	KPhos																							
< 200	All D10	< 4	30 mEq	30 mEq, 20.4 mM																							
200-299	Half D10, half NS	4.5-4	20 mEq	20 mEq, 13.6 mM																							
> 300	All NS	5.5-6	10 mEq	10 mEq, 6.8 mM																							
		> 6	None	None																							
	<b>Electrolyte Abnormalities in DKA</b> Na HCO <sub>3</sub> is not recommended																										
<b>Insulin</b>	Start regular insulin 0.1 units/kg/hr after initial NS bolus completed Stop home insulin pump Review Lantus dosing with Endocrine																										
<b>Labs Monitoring</b>	POC BG hourly BMP/mag/phos and POC BOHB q2hr VBG q2hr until pH > 7.0																										
<b>Physical Monitoring</b>	Full Cardiorespiratory Monitoring VS, neuro assessment hourly																										
<b>Admission Considerations</b>	ICU Admission Indications and Considerations Diabetes Care Flow Chart																										

- Evidence**  
Diabetic Ketoacidosis in Children [?]  
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar: State [?]  
**CHOP Programs**  
Diabetes Center for Children  
**Refer to CHOP >**  
**Podcast**  
PEH Podcast, DKA  
**Related Links**  
American Diabetes Association [?]  
CDC Diabetes Public Health Resource [?]  
National Diabetes Information Clearinghouse [?]






# ED DKA Care Path






# ED DKA Care Path





# Primary Care: Headache Pathway



Posted: October 2023  
Last Revised: August 2025  
Authors: D. Elliott, MD; C. Sperkka, MD; D. Stephenson, MD; J. Zook, PharmD  
Editors: Clinical Pathways Team






# Primary Care: Headache Pathway

## SNOOPY: Snoop for Secondary Headache

<b>S</b>	<p><b>Systemic Disease</b> History of malignancy or tumor History of congenital heart disease Immunosuppression or immune deficiency Hematologic – thrombophilia, thrombocytopenia, coagulopathy or sickle-cell disease Genetic disease with predisposition Recent history of head trauma</p> <p><b>Signs of Systemic Disease</b> Constitutional – weight loss, fever, fatigue, malaise, morning vomiting or recurrent vomiting without cause Infectious – sinusitis, encephalitis/meningitis, tickborne Rheumatologic – arthritis, rash</p>
<b>N</b>	<p><b>Neurologic Signs</b> Altered mental status Papilledema Focal neurologic findings New seizure</p>
<b>O</b>	<p><b>Onset Sudden</b> Thunderclap headache – may signal vascular cause</p>
<b>O</b>	<p><b>Occipital Location</b> May be risk factor for secondary headache</p>
<b>P</b>	<p><b>Progressive</b> Chronic or acutely progressive pattern</p> <p><b>Precipitated by Valsalva</b> Cough or sneeze triggering a headache may signal increased or decreased ICP</p> <p><b>Positional</b> Worse lying down, awakens patient at night when previously no headache or severe upon awakening may signal increased ICP Persistently worse with standing may be dehydration, decondition, low blood pressure, or low ICP</p>
<b>Y</b>	<p><b>Years &lt; 6</b> Risk factor for secondary headache (may be due to limited ability to describe headache)</p>



# Primary Care: Enhanced Note Templates

My Note

Progress Notes - General Pediatrics

Headache Management Tool

{Press to open SmartForm and start documenting. :100100}

## Headache Management Tool

{You MUST complete the ADDITIONAL headache ECONSULT to neurology for this patient. :100100}

Do you want to ask additional headache ques

NoteWriter

Headache Management Tool

Persistent confusion	Altered consciousness
Thunderclap headache	Headache with seizure
Abnormal neurologic exam	Increased intracranial pressure signs
Meningeal signs	

None Apply

Expedited Neurology Referral

Please answer ALL questions listed below to receive referral recommendation:

Are any of the following present?

Recurrent or persistent early morning vomiting?	<input type="checkbox"/>	Yes	No
Unsteady gait with the headache?	<input type="checkbox"/>	Yes	No
Headache in the BACK of the head ONLY?	<input type="checkbox"/>	Yes	No
Unexplained recent weight loss?	<input type="checkbox"/>	Yes	No
Headache frequently waking them from sleep?	<input type="checkbox"/>	Yes	No
Headache continuous or increasingly frequent for 2 weeks?	<input type="checkbox"/>	Yes	No
Six years of age or younger?	<input type="checkbox"/>	Yes	No

**For headache medications, management, or to place an order for eConsult or in-person (Standard or Expedited) referral, click on the link. For headaches that are >1x/wk or disabling, consider having the patient start preventive vitamins.**

Headache Management link

This recommendation appears because you selected "yes" 1-2 times for the above questions

This form is complete; return to the note to complete "Document next steps for Headache Management" and choose the appropriate plan

Create Note Acute 1 AI Acute 2 Concuss. 3 CHATBOT 4

My Note

Progress Notes - General Pediatrics - 10/21/2025 10:58 AM

Headache Management Tool

Arial 11 B I U A

The following are present:

There is NO persistent confusion, altered consciousness, thunderclap headache, headache with seizure, abnormal neurologic exam, increased intracranial pressure signs and meningeal signs

Are any of the following present?

Recurrent or persistent headache? No  
Unsteady gait with the headache? No  
Headache in the BACK of the head only? No  
Unexplained recent weight loss? No  
Headache frequently waking them from sleep? No  
Headache continuous or increasingly frequent for two weeks? **Yes**  
Six years of age or younger? No

{You MUST complete the ADDITIONAL headache questions if you are going to place an ECONSULT to neurology for this patient. :100100}

Do you want to ask additional headache questions? -

Sign when Signing Visit Accept Cancel



## HEADACHE MANAGEMENT (TPP) - Primary Care - 2025

 Leave Feedback

### CHOP Primary Care Headache Pathway

#### Goals

- Identify children who need further evaluation (e.g., brain imaging) for headache
- Ensure timeliness of the evaluation
- Initiate appropriate migraine treatment, including acute and preventative therapy
- Reinforce lifestyle factors as an important part of treatment

#### ▼ Diagnosis

Select a diagnosis and sign the smartset to trigger Teaching Library Headache resources

- ▶ [Diagnosis - Episodic Headache](#) Click for more
- ▶ [Diagnosis - Chronic Headache](#) Click for more
- ▶ [Acute Treatment - NSAIDs](#)
- ▼ [Prolonged Migraine](#)
  - ▶ [Naproxen](#) Click for more
  - ▶ [Rizatriptan <40 kg](#) Click for more
  - ▶ [Reglan](#) Click for more
  - ▶ [Steroids](#) Click for more
- ▶ [Preventative Treatment - If headaches >1x/wk or disabling consider preventative vitamins](#)
- ▶ [Acute Treatment - Triptans - Once at the onset of the headache May repeat dose one time, 2 hours after first dose](#)
- ▶ [Acute Treatment - Antiemetics](#)
- ▼ [Referral to Neurology](#)





# ED, UC, Primary Care: Otitis Media Pathway


## Clinical Pathway for Evaluation/Treatment of Suspected Acute Otitis Media in Children 2 Months to 12 Years

[Goals and Metrics](#)

[Patient Education](#)

### Evidence

[The Diagnosis and Management of Acute Otitis Media](#)



Antibiotic Durations by Age	
< 2 yrs	10 days
2-5 yrs	7 days
≥ 6 yrs	5 days





# ED Otitis Media Discharge Smart Set

## Antibiotics for Otitis Media

**Age >= 6 years:** 5 days of therapy recommended per [CHOP pathway/AAP guidelines](#)

### Antibiotics - Recommended 1st Line

- amOXicillin 400 MG/5ML Oral suspension
- amOXicillin 250 mg Oral capsule
- amOXicillin 500 mg Oral capsule
- amOXicillin 125 mg Oral chewable tablet
- amOXicillin 250 mg Oral chewable tablet

▶ **Antibiotics - Amoxicillin Failure, Recent Amoxicillin Use (Last 30 days), or Associated Conjunctivitis** [Click for more](#)

▶ **Antibiotics - Penicillin Allergy** [Click for more](#)

▶ **Safety-Net Antibiotic Prescription "Wait and See" (NON-severe illness)** [Click for more](#)

**Age >= 6 years:** 5 days of therapy recommended per [CHOP pathway/AAP guidelines](#)

### Antibiotics - Recommended 1st Line

amOXicillin 400 MG/5ML Oral suspension

Reference: [1. CHOP Formulary](#)    [2. Dose](#)    [3. Food Drug Interaction](#)

Links:

Order Inst.: [Dosing INTERVAL change necessary in RENAL i...](#)

Product: **AMOXICILLIN 400 MG/5ML OR SUSP**

Sig Method:

Dose:

- 
- 
- 
- 
- 
- 

Weight Type:

Weight: 23.3 kg

Dosing weight: 23.3 kg (recorded 4 hours ago)

Prescribed Dose: 1,040 mg (44.6 m ... ⌵

Prescribed Amount: 13 mL ⌵

Route:

Frequency:

Duration:

UVUW




# Clinical Pathways Program - 2022

  
Clinical  
Pathways  
Program  
  
2022





# Overall Adherence to AOM Guidelines



Antibiotic Days Saved  
**12,129**





# Overall Adherence to AOM Guidelines



Antibiotic Days Saved  
**111,560**





# Clinical Pathways Program - 2022


  
Clinical  
Pathways  
Program  
  
2022





# Clinical Pathways Program - Current

  
Clinical Pathways Program  
Current





# Clinical Pathways Team



**Medical Director**  
[Jane Lavelle, MD](#)



**Program  
Manager**  
[Becca Kasper, RN](#)



**Associate Medical  
Director**  
[Brandon Ku, MD](#)



**Improvement  
Advisor**  
[Pamela Wentz, RN](#)



**Improvement  
Advisor**  
Kathy Houg, CRNP



**Improvement  
Advisor**  
[Nina Capoferri, RN,  
BSN](#)



**Senior Interactive  
Designer**  
Stephen Crawford,  
BS



**Physician  
Partner, Hospital  
Medicine**  
[Emily Roumm Kane,  
MD, MS](#)



**Physician  
Partner, ICU**  
[Heather Wolfe, MD](#)




**Physician  
Partner, Primary  
Care**  
[Joshua Sperling, MD](#)





# Clinical Pathways Program - Current

  
Clinical Pathways Program  
Current





# Clinical Pathways Program - Future

Clinical Pathways Program  
Future





Thank You

**There is  
always a  
better way.**

THOMAS A. EDISON

